Trade Castle Biosciences, Inc. - CSTL CFD

Castle Biosciences Inc. Company profile

About Castle Biosciences Inc

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company. The Company provides physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company markets its three dermatologic products, DecisionDx-Melanoma, DecisionDx-SCC and DecisionDx DiffDx-Melanoma. It also market DecisionDx-UM, a gene expression profiling (GEP) test. It developed and market DecisionDx-Melanoma to healthcare providers for use with patients diagnosed with invasive cutaneous melanoma. It developed DecisionDx-SCC, a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors. It developed DecisionDx DiffDx-Melanoma, a GEP test designed to be used as an adjunct to histopathology when the distinction between a benign lesion and melanoma is uncertain.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Castle Biosciences Inc revenues increased 50% to $94.1M. Net loss increased from $10.3M to $31.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling, General and Administrative. increase of 68% to $70.9M (expense), Research & Development - Balancing value increase from $11.7M to $24.9M (expense).